Neuromelanin‐Sensitive Magnetic Resonance Imaging of the Nigral Halo Sign in Pediatric β‐Propeller Protein–Associated Neurodegeneration
Movement Disorders Clinical Practice · 05.11.2026
DOI: 10.1002/mdc3.70908 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders Clinical Practice, online erschienen am 05.11.2026. Verfasst von Yun Soo Kim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Pusan National University School of Medicine, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Pusan National University Yangsan Hospital.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Pusan National University School of Medicine, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea.
- Department of Radiology, Pusan National University School of Medicine, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea.
ORCID-Profile: Yun Soo Kim, Hye Jin Baek, Jae-Hyeok Lee
Förderung
- Pusan National University Yangsan Hospital
Zitieren
APA
Kim, Y. S., Baek, H. J., & Lee, J. H. (2026). Neuromelanin‐Sensitive Magnetic Resonance Imaging of the Nigral Halo Sign in Pediatric β‐Propeller Protein–Associated Neurodegeneration. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.70908
Vancouver
Kim YS, Baek HJ, Lee JH. Neuromelanin‐Sensitive Magnetic Resonance Imaging of the Nigral Halo Sign in Pediatric β‐Propeller Protein–Associated Neurodegeneration. Movement Disorders Clinical Practice. 2026. doi:10.1002/mdc3.70908
BibTeX
@article{Kim2026,
author = {Kim, Yun Soo and Baek, Hye Jin and Lee, Jae-Hyeok},
title = {Neuromelanin‐Sensitive Magnetic Resonance Imaging of the Nigral Halo Sign in Pediatric β‐Propeller Protein–Associated Neurodegeneration},
journal = {Movement Disorders Clinical Practice},
year = {2026},
doi = {10.1002/mdc3.70908}
}
EUVIMED